Moreover, the Company is adding to a Phase 2 oral estriol drug for the treatment of backsliding dispatching various sclerosis (MS) and subjective brokenness in Mississippi, and in partnershipwith Intrexon Corporation (XON), a monoclonal counter acting agent blend for the treatment of Pertussis and biotherapeutics for the treatment of phenylketonuria (PKU). According to Zacks Research, the stock has been handed a 1.8 rating on a consensus basis based on the analysts polled. Shares of BioMed Realty Trust Inc. rose by 6.75% in the last five trading days and 13.01% for the last 4 weeks. The stock has a 50 day moving average of $23.63 and a 200-day moving average of $24.74. The company reported $0.58 EPS for the quarter, topping analysts’ consensus estimates of $0.49 by $0.09. The company earned $96.70 million during the quarter, compared to the consensus estimate of $96.87 million. The business’s revenue was down 3.2% on a year-over-year basis. For the next year, analysts anticipate that the firm will report earnings of $5.20 per share, with EPS estimates ranging from $4.93 to $5.29.
Advertisement
Among the analysts, the highest expected of earnings per a share was $ 0.66, and the lowest is $ 0.65.
The firm also recently declared a quarterly dividend, which was paid on Friday, August 28th. The ex-dividend date of this dividend was Thursday, August 13th. The dividend is equivalent to an annualized dividend of $1.04 per ordinary share.
BMR has been the topic of a number of other reports.
After BMO Capital and KeyBanc assigned a Buy rating to BioMed Realty Trust in the last month, the company received another Buy, this time from Canaccord Genuity.
Biomed Realty Trust (NYSE:BMR) had its price objective decreased by Mizuho from $23.00 to $21.00 in a research note published on Monday, AnalystRatingsNetwork.com reports. The rating is an average of the various different ratings given by analysts and brokers, and then averaged into one rating by the good people at Zacks Research in Chicago, IL.
Shares of Biomed Realty Trust (NYSE:BMR) ended Thursday session in red amid volatile trading. They noted that the move was a valuation call.
Advertisement
Shares of Independence Realty Trust, Inc. The Company is engaged in owning, acquiring, developing, leasing and managing laboratory and office space for the life science industry. The Company’s operations are conducted through, directly or indirectly, Agree Limited Partnership (Operating Partnership), of which the Company is the sole general partner, and in which it 96.59% interest as of December 31, 2011. Digital Realty Trust, L.P. holds substantially all the assets of the Company and holds the ownership interests in the Companys joint ventures. The Pennsylvania segment includes properties in Delaware Chester and Montgomery counties.
